Health Care • Biotechnology: Pharmaceutical Preparations
$0.53 ▼ -0.01
(-1.24%)
MKT CAP: $10.7M • VOL: 57.2K
52W L $0 52W H $10
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
TPST // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$26.6M | -$42.0M | -$29.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$26.3M | -$41.8M | -$29.5M |
| EBITDA (Normalized) | -$26.6M | -$41.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$26.8M | -$33.0M | -$27.4M |
| Capital Expenditures (CapEx) | $0 | $435.0K | — |
| Free Cash Flow (FCF) | -$26.8M | -$33.5M | -$27.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.7M | $30.3M | — |
| Total Debt (Short + Long Term) | — | $0 | — |
| Total Stockholders' Equity | $6.7M | $19.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TPST.